Knowing that a supplement is "absorbed" is only half the story. The more important question — and the one that separates genuinely effective joint supplements from expensive placebos — is whether the active compound reaches the specific tissue where it is needed. For hyaluronic acid, that tissue is the synovial membrane and the fluid-filled cavity of your joints. This article traces the complete journey, from the moment a liposomal HA capsule is swallowed to the point where HA is incorporated into synovial fluid.

First: Why Your Joints Are Depleted in the First Place

To appreciate why delivering HA to joints matters, it helps to understand what happens to joint fluid as we age. Healthy synovial fluid is a remarkable biological substance — a viscous, straw-coloured liquid that fills the space between articulating bones. Its primary structural component is hyaluronic acid, present at concentrations of 2–4 mg/mL in a healthy young adult, with molecular weights typically between 1 and 4 million Daltons.^[1]

This high-molecular-weight HA is what gives synovial fluid its characteristic viscoelasticity — the property that allows it to behave like a viscous liquid under slow loads (absorbing shock) and like an elastic solid under rapid loads (resisting impact). Without adequate HA, the fluid becomes thin and watery, cartilage surfaces grind against each other, and the inflammatory cascade of osteoarthritis accelerates.

After age 40, endogenous HA production declines by approximately 50%, and the HA that remains is progressively degraded to lower molecular weights — losing its viscoelastic properties in the process.^[2] In osteoarthritic joints, HA concentration can fall to as low as 1 mg/mL, and molecular weight drops precipitously, leaving a thin, watery fluid with minimal lubricating capacity.

Stage 1: The Capsule Opens — Surviving the Stomach

The first obstacle any oral supplement faces is the stomach — an environment of pH 1.5 to 3.5, saturated with hydrochloric acid and pepsin. For unprotected HA, this is already a hostile environment. While HA is not a protein and is not directly cleaved by pepsin, the acidic conditions begin to depolymerise the molecule, reducing its molecular weight before it even reaches the small intestine.

A liposomal formulation changes this equation fundamentally. The phospholipid bilayer encasing the HA is chemically stable in acidic conditions. It does not dissolve in stomach acid the way a conventional capsule shell does. The HA remains sequestered inside the aqueous core of the liposome, protected from both acid depolymerisation and enzymatic attack. The liposome passes through the stomach largely intact, delivering its cargo to the small intestine in a preserved, high-molecular-weight state.

Stage 2: The Small Intestine — Where Absorption Happens

The small intestine is the primary site of nutrient absorption in the human body. Its inner surface is lined with finger-like projections called villi, each covered in even smaller microvilli — collectively creating a surface area of approximately 250 square metres in an adult. Within each villus runs a central lymphatic vessel called a lacteal, surrounded by a capillary network.

For conventional HA, the small intestine presents a near-insurmountable barrier. The tight junctions between enterocytes (gut lining cells) exclude large molecules, and the molecule's hydrophilicity prevents it from partitioning into the lipid-rich cell membrane. The result is the 5–7% absorption rate documented in radiolabeled studies.

Liposomes exploit two distinct absorption pathways that are simply unavailable to free HA:

Stage 3: The Lymphatic Highway — Bypassing the Liver

This is the stage that most people overlook, and it is arguably the most important. When a molecule is absorbed through the conventional portal route — through the gut wall into the portal vein — it travels directly to the liver, where it undergoes "first-pass metabolism." The liver is extraordinarily efficient at processing and clearing foreign molecules, and many compounds lose the majority of their bioactivity before they ever reach systemic circulation.

Liposomal HA takes a different route. Lipid-based particles absorbed via the lacteals of the gut villi enter the intestinal lymphatic system directly. From there, they travel through the mesenteric lymph nodes, up the thoracic duct, and empty into the subclavian vein — entering systemic circulation at the heart, having bypassed the liver entirely.^[3]

This lymphatic pathway is not merely theoretical. Studies on liposomal drug delivery have consistently demonstrated that lipid-based formulations achieve higher systemic exposure than equivalent oral doses of free compounds, specifically because of this lymphatic absorption route.^[4] The lymphatic system is also directly connected to joint tissue — the synovial membrane has its own lymphatic drainage, and the lymphatics surrounding joints are in continuous communication with systemic lymph circulation.

Stage 4: The Bloodstream — Targeting Inflamed Tissue

Once in systemic circulation, HA faces the challenge of distribution. The bloodstream carries molecules throughout the body, but not all tissues receive equal exposure. Here, the biology of inflammation works in the supplement's favour in a counterintuitive way.

Inflamed tissues — including osteoarthritic joints — exhibit what pharmacologists call the Enhanced Permeability and Retention (EPR) effect. The blood vessels supplying inflamed tissue become more permeable, allowing larger molecules and particles to extravasate (leak out of the vessel) into the surrounding tissue more readily than in healthy tissue. This is the same mechanism that makes liposomal drug delivery so effective in cancer treatment, and it applies equally to inflamed joints.^[5]

Additionally, HA itself has a biological homing mechanism. CD44 receptors — the primary cell-surface receptor for HA — are upregulated in inflamed synovial tissue. This creates a concentration gradient that preferentially draws circulating HA toward the joint, where receptor density is highest.

Stage 5: The Joint — From Synovial Membrane to Fluid

The final stage of the journey is the transition from blood vessel to synovial fluid. The synovial membrane is a highly vascularised tissue, and its Type B synoviocytes (fibroblast-like cells) are the primary producers of endogenous HA in the joint. These cells express CD44 receptors and are exquisitely sensitive to circulating HA levels.

When HA from the bloodstream reaches the synovial membrane, two things happen simultaneously. First, some HA crosses the synovial membrane directly and enters the synovial fluid — a process facilitated by the high permeability of the synovial vasculature. Second, and more importantly, the arriving HA binds to CD44 receptors on synoviocytes, stimulating them to upregulate their own HA synthesis.^[6]

This dual mechanism — direct deposition plus stimulated endogenous production — explains why the clinical benefits of oral HA supplementation continue to accumulate over time rather than plateauing quickly. The longer the supplementation continues, the more the synoviocytes are stimulated to restore their natural HA output, creating a self-reinforcing cycle of joint fluid restoration.

The Complete Picture: What Happens Inside the Joint

Once HA is present in the synovial fluid at adequate concentrations and molecular weights, its effects are multifaceted. It does not simply act as a lubricant — it is an active biological signalling molecule that orchestrates joint health at multiple levels.

The Timeline: What to Expect

Understanding the journey helps set realistic expectations for supplementation. The effects are not immediate because the pathway involves multiple biological steps — absorption, lymphatic transport, distribution, receptor activation, and upregulation of endogenous production. Clinical trials consistently show the following pattern:

This trajectory — gradual onset, sustained accumulation — is the hallmark of a supplement that is working through genuine biological mechanisms rather than masking symptoms. It is also consistent with what we know about the journey: each stage takes time, and the regenerative effects at the joint level require sustained signalling to reach their full expression.